The Life Sciences and SPAC teams advised Senti Biosciences (“Senti Bio”) in its definitive business combination agreement with Dynamics Special Purpose Corp. (Nasdaq: DYNS) to create a public company focused on next-generation gene circuit-enabled cell and gene therapies. The transaction values the combined company at a pro forma equity value of approximately $600 million, assuming a $10.00 per share price and no shareholder redemptions.
The transaction, which has been approved by each of Dynamics' Board of Directors and Senti Bio's Board of Directors, is expected to be completed in the second quarter of 2022, subject to approval by Dynamics' and Senti Bio’s shareholders and satisfaction, or the waiver of, customary closing conditions identified in the business combination agreement. Upon closing of the transaction, the combined company will be named Senti Biosciences, Inc. and will be led by Tim Lu, MD, PhD, Chief Executive Officer of Senti Bio. The company's common stock plans to list on the Nasdaq Capital Market under the trading symbol “SNTB”.
Senti Bio's mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. To accomplish this, the company is building a synthetic biology platform that may enable us to program next-generation cell and gene therapies with what it refers to as “gene circuits.”
The Goodwin team was led by Jocelyn Arel, Mike Patrone, Maggie Wong, Wei Xu and Jesse Fishman, and included Alicia Tschirhart, Sarah Bock, Morgan Frisoli, Morgan Mordecai, Steven Tjoe, Roger Cohen, Michael Shuster, Kevin Kabler, Brad Smith, Todd Pollock and Andrew Wilson.
For additional details on the transaction, please read the press release.